Timothy J Wilt

University of Minnesota Duluth, Duluth, Minnesota, United States

Are you Timothy J Wilt?

Claim your profile

Publications (310)2105.16 Total impact

  • Source

    Full-text · Dataset · Feb 2016
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: For older men who undergo bone mineral density (BMD) testing, the optimal osteoporosis screening schedule is unknown. Time-to-disease estimates are necessary to inform screening intervals. Methods: A prospective cohort study of 5,415 community-dwelling men aged ≥65 years without hip or clinical vertebral fracture or antifracture treatment at baseline was conducted. Participants had concurrent BMD and fracture follow-up between 2000 and 2009, and additional fracture follow-up through 2014. Data were analyzed in 2015. Time to incident osteoporosis (lowest T-score ≤ -2.50) for men without baseline osteoporosis, and time to hip or clinical vertebral fracture or major osteoporotic fracture for men without or with baseline osteoporosis, were estimated. Results: Nine men (0.2%) with BMD T-scores >-1.50 at baseline developed osteoporosis during follow-up. The adjusted estimated time for 10% to develop osteoporosis was 8.5 (95% CI=6.7, 10.9) years for those with moderate osteopenia (lowest T-score, -1.50 to -1.99) and 2.7 (95% CI=2.1, 3.4) years for those with advanced osteopenia (lowest T-score, -2.00 to -2.49) at baseline. The adjusted times for 3% to develop a first hip or clinical vertebral fracture ranged from 7.1 (95% CI=6.0, 8.3) years in men with baseline T-scores > -1.50 to 1.7 (95% CI=1.0, 3.1) years in men with baseline osteoporosis. Conclusions: Men aged 65 years and older with femoral neck, total hip, and lumbar spine BMD T-scores >-1.50 on a first BMD test were very unlikely to develop osteoporosis during follow-up. Additional BMD testing may be most informative in older men with T-scores ≤-1.50.
    Full-text · Article · Jan 2016 · American journal of preventive medicine
  • Source

    Full-text · Article · Jan 2016
  • Timothy J Wilt · Philipp Dahm
    [Show abstract] [Hide abstract]
    ABSTRACT: Enthusiasm for cancer screening and treatment of screen-detected cancer has led to widespread prostate-specific antigen (PSA) screening, a marked increase in prostate cancer incidence, and high use of surgical, radiation, and androgen deprivation treatment for screen-detected disease. This has occurred in advance of a full understanding of the clinical and financial tradeoffs. Although questions remain whether lifetime benefits outweigh harms and costs, data indicate that this balance is not favorable through at least 15 years. This article outlines a conceptual framework for determining the value of screening strategies according to screening and treatment intensity. We describe 4 main cancer screening goals and examine whether PSA screening and treatment achieve these goals and thus provide high-value care. Available evidence demonstrates that PSA screening provides at best a small reduction in prostate cancer mortality, and no reduction in all-cause mortality. High-intensity PSA screening and treatment currently practiced in the United States result in substantial harms and large health care expenditures-it is low-value care. The health importance of prostate cancer and the financial costs to patients and society require improved detection and treatment strategies that produce greater value to patients. We propose lower-intensity, higher-value options. However, until evidence supports a higher-value alternative to current PSA screening strategies, physicians should recommend against PSA screening, policymakers should encourage reduced screening, and most men should say no to the PSA test.
    No preview · Article · Dec 2015 · Journal of the National Comprehensive Cancer Network: JNCCN
  • [Show abstract] [Hide abstract]
    ABSTRACT: The National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative (KDOQI) has provided evidence-based guidelines for all stages of chronic kidney disease (CKD) and related complications since 1997. The 2015 update of the KDOQI Clinical Practice Guideline for Hemodialysis Adequacy is intended to assist practitioners caring for patients in preparation for and during hemodialysis. The literature reviewed for this update includes clinical trials and observational studies published between 2000 and March 2014. New topics include high-frequency hemodialysis and risks; prescription flexibility in initiation timing, frequency, duration, and ultrafiltration rate; and more emphasis on volume and blood pressure control. Appraisal of the quality of the evidence and the strength of recommendations followed the Grading of Recommendation Assessment, Development, and Evaluation (GRADE) approach. Limitations of the evidence are discussed and specific suggestions are provided for future research.
    No preview · Article · Nov 2015 · American Journal of Kidney Diseases
  • Timothy J Wilt · Kristine E Ensrud

    No preview · Article · Oct 2015 · BMJ (online)
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: In 2006, NKF-KDOQI (National Kidney Foundation-Kidney Disease Outcomes Quality Initiative) published clinical practice guidelines for hemodialysis adequacy. Recent studies evaluating hemodialysis adequacy as determined by initiation timing, frequency, duration, and membrane type and prompted an update to the guideline. Study design: Systematic review and evidence synthesis. Setting & population: Patients with advanced chronic kidney disease receiving hemodialysis. Selection criteria for studies: We screened publications from 2000 to March 2014, systematic reviews, and references and consulted the NKF-KDOQI Hemodialysis Adequacy Work Group members. We included randomized or controlled clinical trials in patients undergoing long-term hemodialysis if they reported outcomes of interest. Interventions: Early versus late dialysis therapy initiation; more frequent (>3 times a week) or longer duration (>4.5 hours) compared to conventional hemodialysis; low- versus high-flux dialyzer membranes. Outcomes: All-cause and cardiovascular mortality, myocardial infarction, stroke, hospitalizations, quality of life, depression or cognitive function scores, blood pressure, number of antihypertensive medications, left ventricular mass, interdialytic weight gain, and harms or complications related to vascular access or the process of dialysis. Results: We included 32 articles reporting on 19 trials. Moderate-quality evidence indicated that earlier dialysis therapy initiation (at estimated creatinine clearance [eClcr] of 10-14mL/min) did not reduce mortality compared to later initiation (eClcr of 5-7mL/min). More than thrice-weekly hemodialysis and extended-length hemodialysis during a short follow-up did not improve clinical outcomes compared to conventional hemodialysis and resulted in a greater number of vascular access procedures (very low-quality evidence). Hemodialysis using high-flux membranes did not reduce all-cause mortality, but reduced cardiovascular mortality compared to hemodialysis using low-flux membranes (moderate-quality evidence). Limitations: Few studies were adequately powered to evaluate mortality. Heterogeneity of study designs and interventions precluded pooling data for most outcomes. Conclusions: Limited data indicate that earlier dialysis therapy initiation and more frequent and longer hemodialysis did not improve clinical outcomes compared to conventional hemodialysis.
    No preview · Article · Oct 2015 · American Journal of Kidney Diseases
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: We conducted a systematic review to evaluate whether caregiver-involved interventions improve patient outcomes among adults with dementia or Alzheimer’s disease. Method: We identified and summarized data from randomized controlled trials enrolling adults with dementia or Alzheimer’s disease by searching MEDLINE, PsycINFO, and other sources. Patient outcomes included global quality of life, physical and cognitive functioning, depression/anxiety, symptom control and management, and health care utilization. Results: We identified 31 trials; 20 compared a caregiver intervention with usual care or usual care with promise of intervention at completion of study period. Fifteen compared one caregiver intervention with another individual or caregiver intervention (active control). Compared with usual care or active controls, caregiver-involved interventions had low to insufficient strength of evidence and did not consistently improve patient outcomes. Discussion: Evidence is insufficient to endorse use of most caregiver interventions to improve outcomes for patients with dementia or Alzheimer’s disease.
    Preview · Article · Jul 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Risks for intermediate- and long-term cognitive impairment after cardiovascular procedures in older adults are poorly understood. To summarize evidence about cognitive outcomes in adults aged 65 years or older at least 3 months after coronary or carotid revascularization, cardiac valve procedures, or ablation for atrial fibrillation. MEDLINE, Cochrane, and Scopus databases from 1990 to January 2015; ClinicalTrials.gov; and bibliographies of reviews and eligible studies. English-language trials and prospective cohort studies. One reviewer extracted data, a second checked accuracy, and 2 independently rated quality and strength of evidence (SOE). 17 trials and 4 cohort studies were included; 80% of patients were men, and mean age was 68 years. Cognitive function did not differ after the procedure between on- and off-pump coronary artery bypass grafting (CABG) (n = 6; low SOE), hypothermic and normothermic CABG (n = 3; moderate to low SOE), or CABG and medical management (n = 1; insufficient SOE). One trial reported lower risk for incident cognitive impairment with minimal versus conventional extracorporeal CABG (risk ratio, 0.34 [95% CI, 0.16 to 0.73]; low SOE). Two trials found no difference between surgical carotid revascularization and carotid stenting or angioplasty (low and insufficient SOE, respectively). One cohort study reported increased cognitive decline after transcatheter versus surgical aortic valve replacement but had large selection and outcome measurement biases (insufficient SOE). Mostly low to insufficient SOE; no pertinent data for ablation; limited generalizability to the most elderly patients, women, and persons with substantial baseline cognitive impairment; and possible selective reporting and publication bias. Intermediate- and long-term cognitive impairment in older adults attributable to the studied cardiovascular procedures may be uncommon. Nevertheless, clinicians counseling patients before these procedures should discuss the uncertainty in their risk for adverse cognitive outcomes. Agency for Healthcare Research and Quality.
    No preview · Article · Jul 2015 · Annals of internal medicine
  • Timothy J Wilt · Russell P Harris · Amir Qaseem
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer screening is one approach to reducing cancer-related morbidity and mortality rates. Screening strategies vary in intensity. Higher-intensity strategies are not necessarily higher value. High-value strategies provide a degree of benefits that clearly justifies the harms and costs incurred; low-value screening provides limited or no benefits to justify the harms and costs. When cancer screening leads to benefits, an optimal intensity of screening maximizes value. Some aspects of screening practices, especially overuse and underuse, are low value. Screening strategies for asymptomatic, average-risk adults for 5 common types of cancer were evaluated by reviewing clinical guidelines and evidence syntheses from the American College of Physicians (ACP), U.S. Preventive Services Task Force, American Academy of Family Physicians, American Cancer Society, American Congress of Obstetricians and Gynecologists, American Gastroenterological Association, and American Urological Association. "High value" was defined as the lowest screening intensity threshold at which organizations agree about screening recommendations for each type of cancer and "low value" as agreement about not recommending overly intensive screening strategies. This information is supplemented with additional findings from randomized, controlled trials; modeling studies; and studies of costs or resource use, including information found in the National Cancer Institute's Physician Data Query and UpToDate. The ACP provides high-value care screening advice for 5 common types of cancer; the specifics are outlined in this article. The ACP strongly encourages clinicians to adopt a cancer screening strategy that focuses on reaching all eligible persons with these high-value screening options while reducing overly intensive, low-value screening.
    No preview · Article · May 2015 · Annals of internal medicine
  • Russell P Harris · Timothy J Wilt · Amir Qaseem
    [Show abstract] [Hide abstract]
    ABSTRACT: Experts, professional societies, and consumer groups often recommend different strategies for cancer screening. These strategies vary in the intensity of their search for asymptomatic lesions and in their value. This article outlines a framework for thinking about the value of varying intensities of cancer screening. The authors conclude that increasing intensity beyond an optimal level leads to low-value screening and speculate about pressures that encourage overly intensive, low-value screening.
    No preview · Article · May 2015 · Annals of internal medicine
  • [Show abstract] [Hide abstract]
    ABSTRACT: The role of fecal microbiota transplantation (FMT) for Clostridium difficile infection (CDI) is not well-known. To assess the efficacy, comparative effectiveness, and harms of FMT for CDI. MEDLINE (1980 to January 2015), Cochrane Library, and ClinicalTrials.gov, followed by hand-searching references from systematic reviews and identified studies. Any study of FMT to treat adult patients with CDI; case reports were only used to report harms. Data were extracted by 1 author and verified by another; 2 authors independently assessed risk of bias and strength of evidence. Two randomized, controlled trials (RCTs); 28 case-series studies; and 5 case reports were included. Two RCTs and 21 case-series studies (516 patients receiving FMT) reported using FMT for patients with recurrent CDI. A high proportion of treated patients had symptom resolution; however, the role of previous antimicrobials is unclear. One RCT comparing FMT with 2 control groups (n = 43) reported resolution of symptoms in 81%, 31%, and 23% of the FMT, vancomycin, or vancomycin-plus-bowel lavage groups, respectively (P < 0.001 for both control groups vs. FMT). An RCT comparing FMT route (n = 20) reported no difference between groups (60% in the nasogastric tube group and 80% in the colonoscopy group; P = 0.63). Across all studies for recurrent CDI, symptom resolution was seen in 85% of cases. In 7 case-series studies of patients with refractory CDI, symptom resolution ranged from 0% to 100%. Among 7 patients treated with FMT for initial CDI, results were mixed. Most studies were uncontrolled case-series studies; only 2 RCTs were available for analysis. Fecal microbiota transplantation may have a substantial effect with few short-term adverse events for recurrent CDI. Evidence is insufficient on FMT for refractory or initial CDI treatment and on whether effects vary by donor, preparation, or delivery method. U.S. Department of Veterans Affairs.
    No preview · Article · May 2015 · Annals of internal medicine
  • J Dik F Habbema · Timothy J Wilt · Ruth Etzioni

    No preview · Article · Apr 2015 · Annals of internal medicine
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Evaluate the effect of outpatient antimicrobial stewardship programs on prescribing, patient, microbial outcomes, and costs. Systematic review Search of MEDLINE (2000 through November 2013), Cochrane Library, and reference lists of relevant studies. We included English language studies with patient populations relevant to the United States (eg, infectious conditions, prescription services) evaluating stewardship programs in outpatient settings and reporting outcomes of interest. Data regarding study characteristics and outcomes were extracted and organized by intervention type. We identified 50 studies eligible for inclusion, with most (29 of 50; 58%) reporting on respiratory tract infections, followed by multiple/unspecified infections (17 of 50; 34%). We found medium-strength evidence that stewardship programs incorporating communication skills training and laboratory testing are associated with reductions in antimicrobial use, and low-strength evidence that other stewardship interventions are associated with improved prescribing. Patient-centered outcomes, which were infrequently reported, were not adversely affected. Medication costs were generally lower with stewardship interventions, but overall program costs were rarely reported. No studies reported microbial outcomes, and data regarding outpatient settings other than primary care clinics are limited. Low- to moderate-strength evidence suggests that antimicrobial stewardship programs in outpatient settings improve antimicrobial prescribing without adversely effecting patient outcomes. Effectiveness depends on program type. Most studies were not designed to measure patient or resistance outcomes. Data regarding sustainability and scalability of interventions are limited. Infect Control Hosp Epidemiol 2014;00(0):1-11.
    Full-text · Article · Feb 2015 · Infection Control and Hospital Epidemiology
  • Hanna E Bloomfield · Andrew Olson · Timothy J Wilt

    No preview · Article · Dec 2014 · Annals of internal medicine
  • [Show abstract] [Hide abstract]
    ABSTRACT: Clinical practice guidelines should be based on the best scientific evidence derived from systematic reviews of primary research. However, these studies often do not provide evidence needed by guideline development groups to evaluate the tradeoffs between benefits and harms. In this article, the authors identify 4 areas where models can bridge the gaps between published evidence and the information needed for guideline development applying new or updated information on disease risk, diagnostic test properties, and treatment efficacy; exploring a more complete array of alternative intervention strategies; assessing benefits and harms over a lifetime horizon; and projecting outcomes for the conditions for which the guideline is intended. The use of modeling as an approach to bridge these gaps (provided that the models are high-quality and adequately validated) is considered. Colorectal and breast cancer screening are used as examples to show the utility of models for these purposes. The authors propose that a modeling study is most useful when strong primary evidence is available to inform the model but critical gaps remain between the evidence and the questions that the guideline group must address. In these cases, model results have a place alongside the findings of systematic reviews to inform health care practice and policy.
    No preview · Article · Dec 2014 · Annals of internal medicine
  • [Show abstract] [Hide abstract]
    ABSTRACT: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the comparative effectiveness and safety of preventive dietary and pharmacologic management of recurrent nephrolithiasis in adults.
    No preview · Article · Nov 2014 · Annals of internal medicine
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To inform the VA Office of Health Promotion and Disease Prevention we conducted a systematic review to examine the effects of cancer screening shared decision making (SDM) interventions. Method: We searched MEDLINE, CINAHL, PsycINFO, and relevant journals from 1995 through 2013 for randomized controlled trials (RCTs) of cancer screening SDM interventions in adults in clinical settings. We extracted key study population and intervention characteristics and the effect of SDM on three outcomes of interest. Outcomes of interest drawn from the Ottawa Decision Support Framework included: (1) Decision Quality (informed, values-based, patient involvement), (2) Decision Action (screening preference/intention, screening behavior), and (3) Decision Impact (decisional conflict, health services use, decision satisfaction). Result: We identified twenty-two eligible RCTs evaluating SDM interventions for: breast (k=2), colorectal (k=3), and prostate (k=17) cancer screening. More than half of all SDM interventions included a values clarification exercise (k=15), but few used a theoretical framework (k=7). SDM intervention effects on outcomes varied. For Decision Quality, knowledge was assessed in the majority of studies (n=19), and in all cases SDM increased knowledge. Studies measured values and patient involvement less often (k=5 and k=11, respectively) and found no consistent effect. Eleven studies assessed Decision Action with no consistent SDM effect of SDM. Screening intention was evaluated for breast (k=2) and prostate cancer (k=9). Three studies assessed screening preference, all colorectal cancer. Screening behavior was assessed in 16 studies, ranging from 2 weeks to 1 year. SDM enhanced Decision Impact as measured by a consistent decrease in decisional conflict (k=12). However, SDM had no consistent effect on health services use (k=6) or decision satisfaction (k=2), though outcomes were infrequently reported. Conclusion: SDM interventions for cancer screening consistently increase patient knowledge and often decrease decisional conflict. However, there have been varying intervention effects on Decision Action or Decision Impact. Research is needed to guide future SDM intervention development to enhance the effect on decision action and impact.
    No preview · Conference Paper · Oct 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Prostate cancer is a common malignancy in men and the worldwide burden of this disease is rising. Lifestyle modifications such as smoking cessation, exercise, and weight control offer opportunities to reduce the risk of developing prostate cancer. Early detection of prostate cancer by prostate-specific antigen (PSA) screening is controversial, but changes in the PSA threshold, frequency of screening, and the use of other biomarkers have the potential to minimise the overdiagnosis associated with PSA screening. Several new biomarkers for individuals with raised PSA concentrations or those diagnosed with prostate cancer are likely to identify individuals who can be spared aggressive treatment. Several pharmacological agents such as 5α-reductase inhibitors and aspirin could prevent development of prostate cancer. In this Review, we discuss the present evidence and research questions regarding prevention, early detection of prostate cancer, and management of men either at high risk of prostate cancer or diagnosed with low-grade prostate cancer.
    Full-text · Article · Oct 2014 · The Lancet Oncology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective. Evaluate the evidence for effects of inpatient antimicrobial stewardship programs (ASPs) on patient, prescribing, and microbial outcomes. Design. Systematic review. Methods. Search of MEDLINE (2000 through November 2013), Cochrane Library, and reference lists of relevant studies. We included English language studies with patient populations relevant to the United States (ie, infectious conditions and prescriptions required for antimicrobials) that evaluated ASP interventions and reported outcomes of interest. Study characteristics and outcomes data were extracted and reviewed by investigators and trained research personnel. Results. Few intervention types (eg, audit and feedback, guideline implementation, and decision support) substantially impacted patient outcomes, including mortality, length of stay, readmission, or incidence of Clostridium difficile infection. However, most interventions were not powered adequately to demonstrate impacts on patient outcomes. Most interventions were associated with improved prescribing patterns as measured by decreased antimicrobial use or increased appropriate use. Where reported, ASPs were generally associated with improvements in microbial outcomes, including institutional resistance patterns or resistance in the study population. Few data were provided on harms, sustainability, or key intervention components. Studies were typically of short duration, low in methodological quality, and varied in study design, populations enrolled, hospital setting, ASP intent, intervention composition and implementation, comparison group, and outcomes assessed. Conclusions. Numerous studies suggest that ASPs can improve prescribing and microbial outcomes. Strength of evidence was low, and most studies were not designed adequately to detect improvements in mortality or other patient outcomes, but obvious adverse effects on patient outcomes were not reported.
    Full-text · Article · Oct 2014 · Infection Control and Hospital Epidemiology

Publication Stats

14k Citations
2,105.16 Total Impact Points


  • 1999-2016
    • University of Minnesota Duluth
      • Medical School
      Duluth, Minnesota, United States
    • National Heart, Lung, and Blood Institute
      베서스다, Maryland, United States
  • 2015
    • University of North Carolina at Chapel Hill
      North Carolina, United States
  • 1991-2013
    • Minneapolis Veterans Affairs Hospital
      Minneapolis, Minnesota, United States
  • 2011
    • Arizona State University
      Phoenix, Arizona, United States
    • University of Aberdeen
      • Academic Urology Unit
      Aberdeen, SCT, United Kingdom
  • 2008-2011
    • University of Minnesota Twin Cities
      • • Division of Health Policy and Management
      • • School of Public Health
      Minneapolis, Minnesota, United States
    • Evidence Based Treatment Centers of Seattle
      Seattle, Washington, United States
  • 2006-2011
    • San Francisco VA Medical Center
      San Francisco, California, United States
    • Monash University (Australia)
      • School of Public Health and Preventive Medicine
      Melbourne, Victoria, Australia
    • University of Washington Seattle
      Seattle, Washington, United States
    • University of Virginia
      Charlottesville, Virginia, United States
  • 2009
    • University of Ottawa
      Ottawa, Ontario, Canada
  • 2002-2009
    • Spokane VA Medical Center
      Spokane, Washington, United States
  • 2007
    • Universidade Federal de São Paulo
      • School of Medicine
      San Paulo, São Paulo, Brazil
  • 2005
    • Sichuan University
      • Department of Urology
      Hua-yang, Sichuan, China
    • Hennepin County Medical Center
      Minneapolis, Minnesota, United States
    • University of California, San Francisco
      • Department of Medicine
      San Francisco, California, United States
  • 2004
    • VA Puget Sound Health Care System
      Washington, Washington, D.C., United States
    • Velindre NHS Trust
      Cardiff, Wales, United Kingdom
  • 2001
    • Massachusetts General Hospital
      • Hospital Medicine Unit
      Boston, Massachusetts, United States
  • 1993-2001
    • United States Department of Veterans Affairs
      Бедфорд, Massachusetts, United States